Last updated on June 2017

Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer


Brief description of study

Germ cell tumors belong to the most chemosensitive malignancies. Paclitaxel in combination with ifosfamide and cisplatin (TIP) has become a common regimen for salvage treatment of germ cell cancer. Cabazitaxel may overcome resistance to docetaxel and paclitaxel and might have clinical activity in patients with metastatic and progressive germ cell tumors.

Detailed Study Description

Patients with metastatic germ cell cancer and relapse after two or more courses of cisplatin-based chemotherapy or after high-dose chemotherapy have a poor prognosis and no curative options. Taxanes in various combinations unfold cytotoxic effects on germ cell tumors resistant to conventional doses of cisplatin. Paclitaxel in combination with ifosfamide and cisplatin (TIP) has become a common regimen for salvage treatment of germ cell cancer. In most patients, however, resistance to paclitaxel, as evidenced by progression occurs.Cabazitaxel has been developed to overcome resistance to docetaxel and paclitaxel. It has shown efficacy in patients progressing during docetaxel therapy in a large phase III trial (TROPIC) in patients with castration-resistant prostate cancer. Furthermore, chemotherapy resistance might be less likely to develop in patients receiving cabazitaxel as compared to other taxanes.

Clinical Study Identifier: NCT02478502

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Gedske Daugaard, MD, PhD

Rigshospitalet
Copenhagen, Denmark
  Connect »

Carsten Bokemeyer, MD, PhD

University Clinic Hamburg Eppendorf
Hamburg, Germany
  Connect »

Jan Oldenburg, MD, PhD

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T)
Meldola, Italy
  Connect »

Helene Negaard, MD, PhD

Oslo University Hospital
Oslo, Norway
  Connect »

Jan Oldenburg, MD, PhD

University Hospital of Uppsala, Department of Oncology
Uppsala, Sweden
  Connect »